Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Halts HSV Vaccine Development After Phase II Failure | Contract Pharma

What are you searching for?

Sign in
Breaking News

GSK Halts HSV Vaccine Development After Phase II Failure

The vaccine candidate did not achieve its primary goal in the TH HSV REC-003 trial.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

GlaxoSmithKline plc (GSK) announced today that its early-stage herpes simplex virus (HSV) vaccine candidate, GSK3943104, has failed to meet the primary efficacy objective in a phase II clinical trial. As a result, the company will not be moving forward with phase III development for this particular vaccine.
 
The decision comes after a thorough analysis of data from the TH HSV REC-003 trial, a combined phase I/II proof-of-concept study designed to assess the potential clinical efficacy of the vaccine. While the vaccine candidate did not achieve its primary goal, GSK emphasized that no safety concerns were identified.
 
Genital herpes remains a significant public health issue with limited treatment options. The failure of GSK3943104 is a setback in the ongoing search for effective vaccines against the disease. However, the company has indicated that it will continue to evaluate the data from this and other studies to inform future research and development efforts in its HSV program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics